MK-7228

MK-7228 is an investigational small molecule developed by Merck Sharp & Dohme (Merck) for the treatment of atherosclerosis and related cardiovascular conditions. While specific details regarding its precise molecular target are often proprietary in early development, it is part of Merck's broader cardiovascular pipeline aimed at addressing residual inflammatory and lipid-related risks in patients with established atherosclerotic cardiovascular disease. The compound is typically evaluated for its ability to modulate biological pathways involved in plaque formation, stabilization, or regression. As of recent clinical updates, MK-7228 has been studied in early-phase clinical trials to assess its safety, tolerability, and pharmacokinetics in human subjects.